Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer.
Bruceine A
Lung metastasis
MEK/ERK pathway
Mitochondrial apoptosis pathway
Triple-negative breast cancer
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
11
08
2023
revised:
20
10
2023
accepted:
20
10
2023
medline:
15
11
2023
pubmed:
26
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC), as the most aggressive subtype of breast cancer, presents a scarcity of miraculous drugs in suppressing its proliferation and metastasis. Bruceine A (BA) is a functional group-rich quassin compound with extensive and distinctive pharmacological activities. Within the present study, we investigated the capabilities of BA in suppressing TNBC proliferation and metastasis as well as its potential mechanisms. The results displayed that BA dramatically repressed the proliferation of MDA-MB-231 and 4T1 cells with corresponding IC
Identifiants
pubmed: 37879215
pii: S0753-3322(23)01582-2
doi: 10.1016/j.biopha.2023.115784
pii:
doi:
Substances chimiques
bruceine A
25514-31-2
Quassins
0
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115784Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of the manuscript entitled.